

A singlicate immunogenicity method to detect anti-PEG antibodies: Pre and post dose of pegylated therapies

Issa Jyamubandi, PhD Principal Scientist



Acknowledgements

A singlicate immunogenicity method to detect anti-PEG antibodies: Pre and post dose of pegylated therapies

Authors: Issa Jyamubandi, Aanya Aamir, Jyotsna Kaur, Alen Sylvester, Richard Hughes, Sophia Li

Abstract

Aims: Pre-existing anti-PEG (Polyethylene glycols) antibodies (APA) may affect the efficacy and safety of pegylated compounds. Omontys[®] and Krystexxa[®] withdrawal, and SARS-CoV-2 RNA vaccines anaphylaxis were all linked to APA. This project aimed to develop and validate a method to detect total antibodies against PEG, pre and post dose.

Materials and Methods: The repetitive linear PEG structure prevented the use of a bridging homogenous format; hence the requirement to use a Solid Phase Extraction and Acid Dissociation (SPEAD) assay coupled with the MSD (Meso Scale Discovery[®]) platform.


Results and conclusion: Using singlicate analysis, the method was validated to successfully detect APA pre- and post-dose, with a crucial aspect of the method being the preparation of an appropriate negative control (NC).



R E S O LIAN BIOANALYTICS

Background

• Polyethylene glycols (PEG)



- Classified as GRAS (Generally Recognized as Safe) by the FDA in 1973
- 36 FDA-approved PEGylated therapeutic drugs
- Increase drug solubility, half-life and decrease self-aggregation
- Used in many household products due to different properties

Commercial use





- **PEG-12**: Provides consistency to the product
- **PEG-40 Castor Oil**: Prevents the liquids in our products from separating



• PEG-6 to PEG-9





THE AFTER DARK FALSE LASH COLLECTION
PEG-20 to PEG-40

Clinical impact




- Anti-PEG prevalence varies (0.2% 72%) depending on method used
- Impact on the therapeutic drug efficacy and safety
- Krystexxa[®] and Omontys[®] were both withdrawn because of strong immunogenicity against protein and PEG moieties
- 41% of patient treated with Krystexxa[®] developed APA
- Individual vaccinated with SARS-CoV-2 RNA that experienced anaphylaxis also had APA, potentially due to the PEG moiety in the lipid nanoparticle
 - What impact is that going to have on Pegylated therapeutic?


Assays to detect APA



- Initially tried APA commercial kits
- They are direct assays and are isotype specific (IgG or IgM)
- The standard homogenous ADA assay approach was not able to detect APA consistently
- ~700 Da of PEG (16 PEG monomers) is sufficient to interact with the APA fab paratope (Justin et al. 2020)
- Suggesting that larger MW PEG may occupy both APA paratopes due to the repetitive sequence




Method development



Method development





- We tried to develop a direct assay inhouse using protein A/G
- High baseline was observed
- Aimed to develop an alternative assay that:
 - Can detect all anti-PEG isotype
 - Can detect anti-methoxy and PEG backbone antibodies
 - Use Generic reagents and that can be adapted using any PEGylated compound






SPEAD method to detect APA






Capture



Detection




SPEAD method to detect APA



APA Screening






- Assay optimized in the screening and confirmatory
- Individuals screening using a generic 1.2 Screening CP and 20% Confirmatory CP
- 32% identified as positive
- Negative samples used for making the NC and CP assessment
- High responder samples used for human anti-PEG purification



Commercial APA vs HR sample RES




- High responder sample demonstrated higher signal compared to the commercial pool
- Demonstrating that surrogate antibodies do not exhibit the same properties as endogenous antibodies

Validation

NC vs Buffer comparison






- NC and the buffer were demonstrated to have a strong correlation in the screening and the confirmatory assay
- Confirming that the NC is truly negative

Cut Point Plates and NC correlation^{R E S O LIAN}

	Sample order							
		S1-S14	S15-S28	S29-S42	S43-56			
Day 1	Plate 1	\checkmark	\checkmark					
	Plate 2			\checkmark	\checkmark			
	Plate 3		\checkmark	\checkmark				
	Plate 4	\checkmark			\checkmark			
Day 2	Plate 1			\checkmark	\checkmark			
	Plate 2	\checkmark	\checkmark					
	Plate 3	\checkmark			\checkmark			
	Plate 4		\checkmark	\checkmark				


Plate order	Analyst 1 Run Order	Analyst 2 Run Order
Day 1	P1, P2, P3, P4	P4, P3, P2, P1
Day 2	P4, P3, P2, P1	P1, P2, P3, P4



- Singlicate assessment using this design generated 448 data points in two days instead of 306 data points using duplicate in three days
- The NC was demonstrated to correlate with individual samples variation




Screening Cut Point



- The robust estimate was used to determine the cut point factor (CPF) of 1.16.
- The false positive samples were spread across all plates, analysts and days.


Confirmatory Cut Point





- The confirmatory cut point was determined to be 23.8%
- The false positive samples were spread across different plates, analysts and days.

EPT assessment



- R E S O LIAN BIOANALYTICS
- Six individual samples identified as negatives and the NC
- Spiked at 5000 ng/mL of commercial anti-PEG
- Serially diluted two-fold
- Titre cut point the same as the sCPF of 1.16
- All the six individual samples and pool serum control were within the acceptance criteria of Median EPT ±1.

Precision and selectivity





	Level	Conc. (ng/mL)	Screen signal respon		Confirm % CV signal response (PC & NC)	
Intra Assay Precision	НРС	5000 16.3		21.0		
	MPC	500	12.4		7.2	
	LPC	300	14.7		3.2	
	NC	N/A	6.3		4.8	
	Level	Conc. (ng/mL)	Screen % CV S/NC ratio (PC), signal (NC)		Confirm % CV % Inhibition (PC), signal (NC)	
Inter Assay Precision	HPC	5000	15.3		3.0	
	MPC	500	18.3		7.3	
	LPC	300	17.9		17.3	
	NC	N/A	7.2		N/A	
	Tier	Pop.	СР (рор)	PC level	Met criteria	
	Screen	Healthy matrix	1.16	Blank	10/10	
Selectivity				LPC (300 ng/mL)	10/10	
				Blank	10/10	
	Conf.		23.8%	LPC (300 ng/mL)	10/10	
Haemolysis Selectivity	No effect up to 300 ng/mL (LPC)					
Lipemic Selectivity	No effect up to 300 ng/mL (LPC)					

- Intra assay precision
 acceptable across all the
 PCs and the NC
- Confirming that the use of Singlicate has no impact
 - Inter assay precision
 acceptable across all the
 PCs and the NC
 - Selectivity acceptable in the screening and confirmatory

Future considerations

Future considerations





Conclusion



- Homogenous assay are not suitable to assess anti-peg antibodies
- This generic SPEAD method can be used to assess APA in samples pre and post dose of pegylated therapeutic
- NC screening is crucial for assays with pre-existing antibodies
- The use of singlicate generates 448 data points instead of the 306 and can be performed over 2 days instead of 3 days
- The use of SPEAD method can avoid development of multiple assays to characterise ADA for pegylated compounds



Acknowledgements

A singlicate immunogenicity method to detect anti-PEG antibodies: Pre and post dose of pegylated therapies

Authors: Issa Jyamubandi, Aanya Aamir, Jyotsna Kaur, Alen Sylvester, Richard Hughes, Sophia Li

Abstract

Aims: Pre-existing anti-PEG (Polyethylene glycols) antibodies (APA) may affect the efficacy and safety of pegylated compounds. Omontys[®] and Krystexxa[®] withdrawal, and SARS-CoV-2 RNA vaccines anaphylaxis were all linked to APA. This project aimed to develop and validate a method to detect total antibodies against PEG, pre and post dose.

Materials and Methods: The repetitive linear PEG structure prevented the use of a bridging homogenous format; hence the requirement to use a Solid Phase Extraction and Acid Dissociation (SPEAD) assay coupled with the MSD (Meso Scale Discovery[®]) platform.

Results and conclusion: Using singlicate analysis, the method was validated to successfully detect APA pre- and post-dose, with a crucial aspect of the method being the preparation of an appropriate negative control (NC).


LIAN means integrity

R E S O L I A N

Resolvers Resolute



Anti-AAV antibodies detection, Screening



 The high prevalence of anti-AAV in the general population (>70%) meant production of a true negative control (NC) serum pool was challenging.

The identification of a true NC pool was an essential reagent for the successful validation of the immunogenicity assay to detect anti-AAV antibodies in human matrix, pre- and postgene therapy.

RESOLIAN

Proven expertise. Worldwide access.